Best wishes from SunWay Biotech
- Author: sunway
- Category: Company News
Warmest thoughts and best wishes for a wonderful Christmas and a Happy New Year.Wishing you a Happy Holiday season from your friends at SunWay Biotech.
Our office will only be closed for New Years Day from 31 December to 2 January and will get back to regular operation starting from 3 January. For emergencies during this period, please contact us by email. We will get back to you as soon as possible.
Related posts
ANKASCIN® 568-R – When science meets both market trend and government policies
“The superior effects of MS and AK in ANKASCIN® 568-R show significant results, from managing glycation and inflammation to improving hyperglycemia, hyperlipidemia, hypertension, and cognitive health. This novel ingredient is clinically proven, safe, has multiple applications in dietary supplements and functional food, is compliant with EU and US regulations, and provides excellent support for healthy aging.” According to the WHO, around one in ten people in Europe or US has diabetes, which means that if you go out with your relatives, there’s a good chance that the person you’re arm-in-arm with is someone who has diabetes. Chronic diabetic complications, including hyperlipidemia, hypertension, or Alzheimer’s disease, have been related to advanced glycation end product (AGE) accumulation. Glycation and AGEs lead to accelerated organ aging, thus causing the vicious cycle of tissue glycation and aging. However, the Western diet, which is full of AGEs, and COVID-19 have aggravated this already grim scenario. Reports show that patients with hyperglycemia and COVID-19 have a 2-to-4-fold risk of severe COVID-19 or death than those without diabetes. ANKASCIN® 568-R is a state-of-the-art ingredient containing high MS and AK levels. It addresses the root cause, mainly via PPARγ/Nrf2 pathways, to manage anti-glycation, antioxidant, and anti-inflammation and acts synergistically in improving the impairment of pancreatic β-cell function (blood glucose regulation), resolving lipid plaque accumulation in the blood […]
- Author: sunway
- Category: Company News
Exciting News! XYMOGEN Red Yeast Rice has been recognized as a finalist for the Nutraingredients USA Awards 2024!
🌟 Exciting News! #XYMOGEN Red Yeast Rice has been recognized as a finalist for the Nutraingredients USA Awards 2024: Botanical Product of the Year! 🌟 This marks our third consecutive nomination! #ANKASCIN568R is a clinically proven, cutting-edge ingredient featured in 130 SCI publications, supporting #5in1 health benefits. These benefits include activity against advanced glycation end products (AGEs), support for the body’s inflammatory response (cytokine balance), and improvements in blood sugar management, heart health, weight management, and cognitive health, all of which promote metabolic health and healthy aging. The uniqueness of this ingredient lies in its high levels of two active compounds, Monascin and Ankaflavin, and it is especially noteworthy for being free of #MonacolinK (statins). By activating #Nrf2 and #PPARs, it addresses core aging issues, including AGEs, inflammatory cytokines, and oxidative stress, while also enhancing lipid metabolism and insulin sensitivity. We deeply appreciate the relentless commitment of our R&D teams and the robust support from our customers. Join us in supporting XYMOGEN Red Yeast Rice as we aim for the top prize! 💪 For more info: https://www.nutraingredients-usa.com/Article/2024/05/22/NutraIngredients-USA-Awards-2024-finalists-announced #NutraingredientAsia #Finalist #antiaging #CardiovascularHealth #BloodSugarManagement #NIUawards23 #RedYeastRice
- Author: sunway
- Category: Company News
Interview from PharmaBoardRoom: George J. Lee, Ph.D. – Chairman; Tzu-Ming Pan, Ph.D – Vice Chairman and Chief Technology and Science Officer, SunWay Biotech, Taiwan
George Lee and Tzu-Ming Pan introduce SunWay Biotech’s groundbreaking red yeast rice extract, ANKASCIN® 568-R, which has been recognized as a New Dietary Ingredient by the US FDA. SunWay Biotech is now bringing this unique product onto the global stage and are considering developing a pharmaceutical product based on the same compounds.
- Author: sunway
- Category: Company News